VANCOUVER, BC, Aug. 24, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company’s Advisory Council. Konstantin Adamsky, PhD, is the Chief Operating…
